CXCL5 stimulation of RANK ligand expression in Paget's disease of bone

Laboratory Investigation

Volumn 93, Issue 4, 2013, Pages 472-479

  Sundaram, Kumaran ^a   Rao, D Sudhaker ^b   Ries, William L ^c   Reddy, Sakamuri V ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

CXCL5; measles virus nucleocapsid protein (MVNP); osteoclast; Paget's disease of bone; RANK ligand

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; MEASLES VIRUS NUCLEOCAPSID PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; NUCLEOCAPSID PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; CHROMATIN IMMUNOPRECIPITATION; GENE ACTIVITY; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PAGET BONE DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; CELL LINE; CHEMOKINE CXCL5; CREB-BINDING PROTEIN; HUMANS; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; OSTEITIS DEFORMANS; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 84875714381     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.5     Document Type: Article

References (45)

1. Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget's disease of bone. J Bone and Miner Res 2006;21(Suppl 2):P58-P63.
2. Hocking LJ, Lucas GJ, Daroszewska A, et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet 2002;11:2735-2739.
3. Singer FR, Mills BG. Viruses and Paget's disease. Lancet 1983;1:69.
4. Kurihara N, Reddy SV, Menaa C, et al. Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J Clin Invest 2000;105:607-614.
5. Kurihara N, Zhou H, Reddy SV, et al. Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice. J Bone Miner Res 2006;21:446-455.
6. Nakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275:768-775.
7. Lee SK, Kalinowski J, Jastrzebski S, et al. 1, 25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. J Immunol 2002;169: 2374-2380.
8. Rossa C, Ehmann K, Liu M, et al. MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells. J Interferon Cytokine Res 2006;26:719-729.
9. Menaa C, Reddy SV, Kurihara N, et al. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest 2000;105:1833-1838.
10. Sun SG, Lau YS, Itonaga I, et al. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation. J Pathol 2006;209:114-120.
11. Neale SD, Schulze E, Smith R, et al. The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease. QJM 2002;95:233-240.
12. Roodman GD, Kurihara N, Ohsaki Y, et al. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 1992;89:46-52.
13. Sundaram K, Senn J, Yuvaraj S, et al. FGF-2 stimulation of RANK ligand expression in Paget's disease of bone. Mol Endocrinol 2009;23: 1445-1454.
14. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukocyte Biol 2000;68:1-8.
15. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-127.
16. Walz A, Schmutz P, Mueller C, et al. Regulation and function of the CXC chemokine ENA-78 in monocytes and its role in disease. J Leukocyte Biol 1997;62:604-611.
17. Li A, King J, Moro A, et al. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol 2011;178:1340-1349.
18. Koch AE, Kunkel SL, Harlow LA, et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994;94:1012-1018.
19. Sun H, Chung WC, Ryu SH, et al. Cyclic AMP-responsive element binding protein-and nuclear factor-kappaB-regulated CXC chemokine gene expression in lung carcinogenesis. Cancer Prev Res (Phila) 2008; 1:316-328.
20. Wright LM, Maloney W, Yu X, et al. Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone 2005;36:840-853.
21. Yu X, Collin-Osdoby P, Osdoby P. SDF-1 increases recruitment of osteoclast precursors by upregulation of matrix metalloproteinase-9 activity. Connect Tissue Res 2003;44(Suppl 1):79-84.
22. Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002;100:2195-2202.
23. Sambandam Y, Sundaram K, Liu A, et al. CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment. Oncogene 2012;32:97-105.
24. Sundaram K, Mani SK, Kitatani K, et al. DACH1 negatively regulates the human RANK ligand gene expression in stromal/preosteoblast cells. J Cell Biochem 2008;103:1747-1759.
25. Roccisana JL, Kawanabe N, Kajiya H, et al. Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells. J Biol Chem 2004;279: 10500-10507.
26. Reddy SV. Etiology of Paget's disease and osteoclast abnormalities. J Cell Biochem 2004;93:688-696.
27. Stadnyk AW, Carrigan SO, Otley AR. Neutrophil transintestinal epithelial migration to CXCR2 ligands is regulated by adenosine. J Pediatr Gastroenterol Nutr 2012;54:414-421.
28. Schauer IE, Knaub LA, Lloyd M, et al. CREB downregulation in vascular disease: a common response to cardiovascular risk. Arterioscler Thromb Vasc Biol 2010;30:733-741.
29. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-253.
30. Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
31. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002;2:664-674.
32. Ha J, Choi HS, Lee Y, et al. CXC chemokine ligand 2 induced by receptor activator of NF-kappa B ligand enhances osteoclastogenesis. J Immunol 2010;184:4717-4724.
33. Lisignoli G, Cristino S, Toneguzzi S, et al. IL1beta and TNFalpha differently modulate CXCL13 chemokine in stromal cells and osteoblasts isolated from osteoarthritis patients: evidence of changes associated to cell maturation. Exp Gerontol 2004;39:659-665.
34. Lisignoli G, Toneguzzi S, Piacentini A, et al. Human osteoblasts express functional CXC chemokine receptors 3 and 5: activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and beta-N- acetylhexosaminidase release. J Cell Physiol 2003;194:71-79.
35. Birch MA, Ginty AF, Walsh CA, et al. PCR detection of cytokines in normal human and pagetic osteoblast-like cells. J Bone Miner Res 1993;8:1155-1162.
36. Begley LA, Kasina S, Mehra R, et al. CXCL5 promotes prostate cancer progression. Neoplasia 2008;10:244-254.
37. Fujita K, Janz S. Attenuation of WNT signaling by DKK-1 and-2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 2007;6:71.
38. Kitazawa S, Kitazawa R. Epigenetic control of mouse receptor activator of NF-kappa B ligand gene expression. Biochem Biophys Res Commun 2002;293:126-131.
39. Lee NK, Choi YG, Baik JY, et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 2005;106: 852-859.
40. Bai XC, Lu D, Liu AL, et al. Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast. J Biol Chem 2005;280:17497-17506.
41. O'Brien CA, Gubrij I, Lin SC, et al. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1, 25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 1999;274:19301-19308.
42. Liu J, Yang H, Liu W, et al. Sp1 and Sp3 regulate the basal transcription of receptor activator of nuclear factor kappa B ligand gene in osteoblasts and bone marrow stromal cells. J Cell Biochem 2005; 96:716-727.
43. Fu Q, Manolagas SC, O'Brien CA. Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol 2006;26:6453-6468.
44. Kim S, Yamazaki M, Zella LA, et al. Activation of receptor activator of NF-kappaB ligand gene expression by 1, 2-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol 2006;26:6469-6486.
45. Onal M, Galli C, Fu Q, et al. The RANKL distal control region is required for the increase in RANKL expression, but not the bone loss, associated with hyperparathyroidism or lactation in adult mice. Mol Endocrinol 2012;26:341-348.